Dillon & Associates’s Gilead Sciences GILD Stock Holding History

Dillon & Associates’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-2,750	Closed	-$217K	–	72
2016 Q3	$217K	Sell	2,750 -25	-0.9%	-$2.03K	0.1%	68
2016 Q2	$230K	Sell	2,775 -250	-8%	-$22.2K	0.11%	67
2016 Q1	$278K	Buy	3,025 +150	+5%	+$13.5K	0.13%	61
2015 Q4	$290K	Hold	2,875	–	–	0.14%	58
2015 Q3	$282K	Hold	2,875	–	–	0.14%	61
2015 Q2	$336K	Sell	2,875 -25	-0.9%	-$2.73K	0.16%	56
2015 Q1	$284K	Hold	2,900	–	–	0.14%	58
2014 Q4	$273K	Sell	2,900 -50	-2%	-$5.17K	0.13%	59
2014 Q3	$313K	Hold	2,950	–	–	0.16%	56
2014 Q2	$244K	Buy	2,950 +100	+4%	+$7.78K	0.13%	57
2014 Q1	$202K	Hold	2,850	–	–	0.11%	60
2013 Q4	$214K	Buy	+2,850	New	+$198K	0.12%	58

Other funds holding GILD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Dillon & Associates's GILD Position: Q4 2016 in Review

Dillon & Associates sold out of Gilead Sciences (GILD) in Q4 2016, closing a stake of 2,750 shares — an estimated $217K sold.

Dillon & Associates first reported a position in GILD in Q4 2013 and held it in 12 quarters. The position peaked at $336K in Q2 2015. 1,573 funds tracked by Wall St. Rank hold GILD as of Q4 2016.

Dillon & Associates reported no remaining Gilead Sciences position as of Q4 2016 after selling out during the quarter.
Dillon & Associates sold 2,750 Gilead Sciences shares in Q4 2016, an estimated $217K.
Dillon & Associates first reported a position in Gilead Sciences in Q4 2013 and held it in 12 quarters.
Dillon & Associates's Gilead Sciences position peaked at $336K in Q2 2015.
1,573 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2016.

Based on Dillon & Associates's 13F filing for Q4 2016, filed 2 Feb 2017.